Approved for use within the UK in 2022, TruCheck is allowing people to go beyond what’s currently possible with cancer screening. With a single blood test, TruCheck can detect signals from 70 types of cancer.
The TruCheck test underwent rigorous evaluation in clinical studies involving more than 40,000 participants. Developed by Datar Cancer Genetics, its clinical laboratory boasts certification under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), as well as accreditation by the College of American Pathologists (CAP).
Screening tests serve as an early warning system, identifying potential cancers even before they present symptoms. At present, recommended screening tests are available for just five types of cancer – colorectal, lung (for those at risk), breast, cervical, and prostate. Unfortunately, many other cancers, including pancreatic and ovarian, often remain silent in the early stages, making them more likely to be diagnosed at a later stage.
The benefits of early detection cannot be overstated. When cancer is caught early, before it has a chance to spread, the five-year cancer-specific survival rate quadruples compared to late-stage diagnoses. Early detection is your first line of defense – make it count.
The TruCheck test does not detect all cancer types and not all cancer types can be detected in the blood. False negative and false positive results do occur.
At CancerScan UK Ltd, we are deeply committed to advancing patient care through our cutting-edge early cancer detection technology. Our innovative solutions are designed to seamlessly integrate into health systems, providing invaluable insights that could save lives.
For health systems considering partnering with us, here’s what you can expect:
⦁ Improved Patient Outcomes: Our TruCheck system enables early detection of multiple cancer types, enhancing the possibility of effective treatment and improved survival rates for your patients.
⦁ Efficiency: We issue results within 2-3 weeks after the blood draw, providing timely information that can significantly impact patient care.
⦁ Seamless Integration: Our systems are designed to smoothly integrate with your existing medical systems, ensuring an uninterrupted workflow.
⦁ Clinical Support: Our dedicated clinical team is available to answer any queries and provide necessary support to your healthcare providers.
⦁ Trust and Security: We adhere to stringent privacy and data protection standards to ensure the highest level of confidentiality and security for your patient data.
By partnering with CancerScan UK Ltd, you can ensure a higher standard of care for your patients. To discuss more about our services, please contact us at healthpartners@cancerscanuk.co.uk. We look forward to working together for better patient outcomes.
The TruCheck test is suggested for use in adults with a higher risk of cancer, typically those aged 50 or above. TruCheck does not detect all types of cancers and should be considered a supplemental tool alongside routine cancer screening tests advised by your healthcare provider. The primary goal of TruCheck is to identify cancer signals and predict their origin within the body. It is not recommended for use in individuals who are pregnant, under the age of 40, or currently undergoing active cancer treatment.
Results must be analysed by a healthcare professional, taking into account the patient’s medical history, clinical signs, and symptoms. A result of “No Cancer Signal Detected” does not definitively exclude the presence of cancer. Likewise, a “Cancer Signal Detected” result necessitates further diagnostic evaluation through established medical procedures (such as imaging) to confirm the presence of cancer.
In cases where further testing does not confirm cancer, this could indicate either the absence of cancer or that the test was unable to detect it, including situations where the cancer is located in a different part of the body. Be aware that false-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) results can occur.
1. Akolkar et al. B15: Circulating tumor cells express tissue specific antigens in multiple cancers. Clin Cancer Res.2020;
26(11_Suppl). DOI: 10.1158/1557-3265.LiqBiop20-B15.
2. Akolkar et al. Circulating ensembles of tumor-associated cells: A redoubtable new systemic hallmark of cancer. Int. J.
Cancer:2019; 146, 3485-3494. DOI: 10.1002/ijc.32815.
3. Gaya A et al. Evaluation of circulating tumor cell clusters for pan-cancer noninvasive diagnostic triaging. Cancer Cytopathol.
2020; 129 (3) 226-238 doi: 10.1002/cncy.22366.
4. Ranade A et al. Hallmark Circulating Tumor-Associated Cell Clusters Signify 230 Times Higher One-Year Cancer Risk. Cancer
Prev Res. 2021;14:11-6 DOI:10.1158/1940-6207.CAPR-20-0322.
5. Crook T et al. Accurate Screening for Early-Stage Breast Cancer by Detection and Profiling of Circulating Tumor Cells. Cancers
(Basel). 2022 Jul; 14(14): 3341. DOI: 10.3390/cancers14143341.
